texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Share:

 
 

Panhandle Clinical Trials

Texas Oncology cancer centers in the Texas Panhandle participate in a wide range of clinical trials and groundbreaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the Texas Panhandle area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the Texas Panhandle area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the Texas Panhandle area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the Texas Panhandle area and talk to you doctor to determine which clinical trial is right for you.

Bladder Cancer

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

BMT

Title: Protocol for a research database for hematopoietic cell transplantation, other cellular therapies and marrow toxic injuries. View

Indication: BMT

Location: Texas Oncology-Amarillo Cancer Center

Breast Cancer

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Essential Thrombocythemia

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Hematologic

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-Amarillo Cancer Center

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Leukemia

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Lung Cancer

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Lymphomas

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Melanoma

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Miscellaneous

Title: PNH (Paroxysmal Nocturnal Hemoglobiniuria) Registry View

Indication: Miscellaneous

Location: Texas Oncology-Amarillo Cancer Center

Myelofibrosis

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Myelomas

Title: PREAMBLE - Observational in 1L & R/R MM View

Description: CA204-008: Prospective Research Assessment in Multiple Myeloma: an Observational Evaluation (PREAMBLE)

Indication: Myelomas

Location: Texas Oncology-Amarillo Cancer Center

Title: Observational INSIGHT MM study View

Description: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT MM study (NSMM-5001)

Indication: Myelomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Prostate Cancer

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Skin Cancer

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Solid Tumors

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Urothelial Cancer

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Texas Oncology-Amarillo Cancer Center

Title: Protocol for a research database for hematopoietic cell transplantation, other cellular therapies and marrow toxic injuries. View

Indication: BMT

Location: Texas Oncology-Amarillo Cancer Center

Title: PNH (Paroxysmal Nocturnal Hemoglobiniuria) Registry View

Indication: Miscellaneous

Location: Texas Oncology-Amarillo Cancer Center

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-Amarillo Cancer Center

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: PREAMBLE - Observational in 1L & R/R MM View

Description: CA204-008: Prospective Research Assessment in Multiple Myeloma: an Observational Evaluation (PREAMBLE)

Indication: Myelomas

Location: Texas Oncology-Amarillo Cancer Center

Title: Observational INSIGHT MM study View

Description: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT MM study (NSMM-5001)

Indication: Myelomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

No Phase

Title: Protocol for a research database for hematopoietic cell transplantation, other cellular therapies and marrow toxic injuries. View

Indication: BMT

Location: Texas Oncology-Amarillo Cancer Center

Title: PNH (Paroxysmal Nocturnal Hemoglobiniuria) Registry View

Indication: Miscellaneous

Location: Texas Oncology-Amarillo Cancer Center

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-Amarillo Cancer Center

Title: PREAMBLE - Observational in 1L & R/R MM View

Description: CA204-008: Prospective Research Assessment in Multiple Myeloma: an Observational Evaluation (PREAMBLE)

Indication: Myelomas

Location: Texas Oncology-Amarillo Cancer Center

Phase I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Phase II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Phase III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Phase IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: Observational INSIGHT MM study View

Description: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT MM study (NSMM-5001)

Indication: Myelomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV